Saw palmetto Formula Capsules
Natural health product licensed in Canada
- Licence holder
- BIOVANTEK
- NPN or DIN-HM
- 80067958
- Status
- Inactive licence
- Licence date
- 23 March 2016
- Revision date
- 18 May 2022
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Serenoa repens Source : Fruit Extract : Matériel brut sec Extraction ratio : 2.56:1 Dry plant equivalent : 640 milligramme Potency : 85 Pour cent Free fatty acids, esters, and sterols | 250 milligramme | Not calculated |
Non-medicinal ingredients
Pumpkin seed oil, Stéarate de magnésium, Dioxyde de silicium, Maltodextrine, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 4 Capsule ; minimum: 4 Capsule ; maximum: 4 Capsule | 4 Tous les jours ; minimum: 4 Tous les jours ; maximum: 4 Tous les jours |
Uses authorised in Canada
Helps to maintain normal DNA synthesis. Helps in energy metabolism and in tissue formation. Used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow, incomplete voiding, frequent daytime and night time urination) associated with mild to moderate benign prostatic hyperplasia,.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
No statement required.
- Effets indésirables connus
No statement is required.
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use to exclude a diagnosis of prostate cancer. To exclude the diagnosis of prostate cancer, consult a health care practitioner prior to use.
Source
Official Health Canada record, licence 80067958
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed. Photograph the packaging